| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 40 | 2025 | 1181 | 3.290 |
Why?
|
| Myocardium | 40 | 2025 | 1022 | 1.470 |
Why?
|
| Cognitive Dysfunction | 4 | 2020 | 235 | 1.460 |
Why?
|
| Dietary Supplements | 5 | 2025 | 472 | 1.310 |
Why?
|
| Ultrasonography, Doppler | 10 | 2015 | 193 | 1.280 |
Why?
|
| Heart Failure | 14 | 2023 | 2297 | 1.150 |
Why?
|
| Heart | 17 | 2025 | 731 | 1.080 |
Why?
|
| Cardiovascular Diseases | 9 | 2024 | 1958 | 1.040 |
Why?
|
| Heart Atria | 5 | 2021 | 321 | 1.040 |
Why?
|
| Cardiomegaly | 15 | 2018 | 133 | 1.010 |
Why?
|
| Acetylcysteine | 3 | 2025 | 71 | 1.000 |
Why?
|
| Patient Readmission | 3 | 2020 | 382 | 0.960 |
Why?
|
| Mice | 85 | 2025 | 17740 | 0.930 |
Why?
|
| Glycine | 4 | 2025 | 168 | 0.900 |
Why?
|
| Vitamin B Complex | 1 | 2024 | 40 | 0.890 |
Why?
|
| Blood Flow Velocity | 15 | 2021 | 454 | 0.880 |
Why?
|
| Aorta | 9 | 2021 | 545 | 0.860 |
Why?
|
| Sarcoplasmic Reticulum | 13 | 2013 | 196 | 0.850 |
Why?
|
| Deprescriptions | 1 | 2023 | 12 | 0.830 |
Why?
|
| Coronary Circulation | 5 | 2010 | 211 | 0.830 |
Why?
|
| Hypertension | 7 | 2023 | 1286 | 0.810 |
Why?
|
| Pulmonary Artery | 2 | 2017 | 437 | 0.800 |
Why?
|
| Myocardial Infarction | 11 | 2023 | 1042 | 0.790 |
Why?
|
| Folic Acid | 1 | 2024 | 293 | 0.760 |
Why?
|
| Delirium | 5 | 2021 | 56 | 0.750 |
Why?
|
| Animals | 100 | 2025 | 34304 | 0.730 |
Why?
|
| Dementia | 2 | 2024 | 451 | 0.700 |
Why?
|
| Heart Failure, Diastolic | 2 | 2021 | 11 | 0.680 |
Why?
|
| Cardiovascular Physiological Phenomena | 2 | 2018 | 29 | 0.650 |
Why?
|
| Arteries | 2 | 2011 | 218 | 0.640 |
Why?
|
| Blood Pressure | 11 | 2023 | 1351 | 0.640 |
Why?
|
| Ventricular Remodeling | 12 | 2018 | 184 | 0.620 |
Why?
|
| Hospitalization | 7 | 2021 | 1784 | 0.610 |
Why?
|
| Aged | 40 | 2024 | 19656 | 0.610 |
Why?
|
| Health Education | 1 | 2020 | 221 | 0.590 |
Why?
|
| Ventricular Function, Left | 8 | 2021 | 514 | 0.590 |
Why?
|
| Coronary Vessels | 6 | 2010 | 531 | 0.590 |
Why?
|
| Diet Therapy | 1 | 2018 | 41 | 0.580 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2013 | 99 | 0.560 |
Why?
|
| Mice, Inbred C57BL | 36 | 2025 | 4417 | 0.550 |
Why?
|
| Pulsatile Flow | 5 | 2011 | 127 | 0.550 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 116 | 0.550 |
Why?
|
| Education, Pharmacy | 1 | 2018 | 55 | 0.550 |
Why?
|
| Needs Assessment | 1 | 2018 | 174 | 0.540 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 730 | 0.530 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 6537 | 0.510 |
Why?
|
| Atrial Function, Left | 1 | 2015 | 27 | 0.490 |
Why?
|
| Stroke | 1 | 2023 | 982 | 0.490 |
Why?
|
| Glutathione | 4 | 2025 | 196 | 0.470 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2013 | 340 | 0.470 |
Why?
|
| Fibrosis | 15 | 2022 | 442 | 0.470 |
Why?
|
| Carotid Arteries | 3 | 2004 | 143 | 0.470 |
Why?
|
| Brain | 2 | 2024 | 3014 | 0.450 |
Why?
|
| Hypernatremia | 1 | 2014 | 29 | 0.440 |
Why?
|
| Atherosclerosis | 4 | 2023 | 913 | 0.440 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2022 | 163 | 0.430 |
Why?
|
| Echocardiography | 4 | 2017 | 1067 | 0.430 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2010 | 225 | 0.430 |
Why?
|
| Age Factors | 14 | 2018 | 2815 | 0.420 |
Why?
|
| Myocytes, Cardiac | 14 | 2019 | 641 | 0.420 |
Why?
|
| Isoflurane | 3 | 2009 | 41 | 0.420 |
Why?
|
| Fibroblasts | 10 | 2017 | 887 | 0.420 |
Why?
|
| Aging, Premature | 1 | 2013 | 30 | 0.420 |
Why?
|
| Calcium-Transporting ATPases | 7 | 1996 | 55 | 0.420 |
Why?
|
| Aorta, Thoracic | 2 | 2017 | 526 | 0.410 |
Why?
|
| Angiotensin II | 5 | 2017 | 162 | 0.410 |
Why?
|
| Growth Hormone | 1 | 2013 | 149 | 0.400 |
Why?
|
| Mice, Knockout | 25 | 2021 | 3756 | 0.400 |
Why?
|
| Risk Factors | 15 | 2024 | 10278 | 0.390 |
Why?
|
| Vascular Resistance | 4 | 2009 | 188 | 0.390 |
Why?
|
| Inflammation | 8 | 2023 | 1447 | 0.390 |
Why?
|
| Hospital Mortality | 3 | 2014 | 1027 | 0.380 |
Why?
|
| Apolipoproteins E | 3 | 2009 | 192 | 0.380 |
Why?
|
| Diastole | 8 | 2017 | 177 | 0.380 |
Why?
|
| Transducers | 2 | 2009 | 24 | 0.370 |
Why?
|
| Male | 60 | 2025 | 61443 | 0.370 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2020 | 374 | 0.360 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2011 | 65 | 0.360 |
Why?
|
| Humans | 66 | 2024 | 125110 | 0.360 |
Why?
|
| Nuclear Receptor Coactivator 2 | 3 | 2018 | 201 | 0.350 |
Why?
|
| Heart Diseases | 3 | 2016 | 495 | 0.350 |
Why?
|
| Myocardial Contraction | 6 | 2021 | 265 | 0.330 |
Why?
|
| Blood Volume | 1 | 2010 | 81 | 0.330 |
Why?
|
| Cardiomyopathies | 5 | 2022 | 500 | 0.330 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 84 | 0.320 |
Why?
|
| Blood Pressure Determination | 2 | 2008 | 111 | 0.320 |
Why?
|
| Hemodynamics | 4 | 2011 | 845 | 0.320 |
Why?
|
| Calcium | 10 | 2013 | 1105 | 0.320 |
Why?
|
| Aminoimidazole Carboxamide | 3 | 2022 | 23 | 0.300 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2009 | 53 | 0.300 |
Why?
|
| Female | 46 | 2025 | 66704 | 0.290 |
Why?
|
| Geriatrics | 2 | 2023 | 72 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2016 | 682 | 0.290 |
Why?
|
| Vasodilator Agents | 4 | 2010 | 202 | 0.290 |
Why?
|
| Disease Models, Animal | 17 | 2021 | 4408 | 0.290 |
Why?
|
| Cause of Death | 2 | 2024 | 474 | 0.280 |
Why?
|
| Physical Conditioning, Animal | 4 | 1996 | 93 | 0.270 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 604 | 0.270 |
Why?
|
| Myocardial Reperfusion Injury | 5 | 2013 | 149 | 0.270 |
Why?
|
| Oxidative Stress | 5 | 2025 | 818 | 0.260 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 389 | 0.260 |
Why?
|
| Ribonucleotides | 2 | 2018 | 36 | 0.250 |
Why?
|
| Heart Rate | 5 | 2021 | 582 | 0.250 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2017 | 110 | 0.250 |
Why?
|
| Regional Blood Flow | 3 | 2011 | 209 | 0.230 |
Why?
|
| Patient Selection | 2 | 2024 | 694 | 0.230 |
Why?
|
| Motion | 1 | 2004 | 43 | 0.230 |
Why?
|
| Cardiac Catheterization | 1 | 2008 | 632 | 0.210 |
Why?
|
| Educational Measurement | 3 | 2018 | 323 | 0.210 |
Why?
|
| Models, Animal | 3 | 2017 | 456 | 0.210 |
Why?
|
| Polypharmacy | 1 | 2023 | 40 | 0.200 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 2055 | 0.200 |
Why?
|
| Chemokine CCL2 | 4 | 2017 | 125 | 0.200 |
Why?
|
| Ventricular Pressure | 2 | 2021 | 41 | 0.190 |
Why?
|
| Myocardial Ischemia | 5 | 2015 | 345 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2023 | 3424 | 0.190 |
Why?
|
| Internet | 1 | 2024 | 375 | 0.190 |
Why?
|
| Phospholipids | 3 | 1998 | 105 | 0.190 |
Why?
|
| Geriatric Assessment | 3 | 2021 | 175 | 0.180 |
Why?
|
| Patient Comfort | 1 | 2021 | 4 | 0.180 |
Why?
|
| Frailty | 1 | 2023 | 105 | 0.180 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 19 | 0.180 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2012 | 216 | 0.170 |
Why?
|
| Cells, Cultured | 11 | 2019 | 3044 | 0.170 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 2 | 2011 | 29 | 0.170 |
Why?
|
| Antioxidants | 2 | 2025 | 355 | 0.170 |
Why?
|
| Equipment Design | 4 | 2011 | 590 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2020 | 6123 | 0.170 |
Why?
|
| Home Care Services | 1 | 2021 | 74 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2021 | 114 | 0.170 |
Why?
|
| Mitochondria | 4 | 2023 | 680 | 0.170 |
Why?
|
| Insulin Resistance | 3 | 2023 | 641 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1095 | 0.170 |
Why?
|
| Gene Expression Regulation | 9 | 2013 | 2527 | 0.160 |
Why?
|
| Thrombolytic Therapy | 1 | 2021 | 198 | 0.160 |
Why?
|
| Inflammasomes | 1 | 2021 | 151 | 0.160 |
Why?
|
| Decision Making | 2 | 2023 | 656 | 0.160 |
Why?
|
| Mice, Transgenic | 13 | 2019 | 2414 | 0.160 |
Why?
|
| Macrophages | 4 | 2020 | 626 | 0.160 |
Why?
|
| Infarction | 1 | 2019 | 22 | 0.160 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 462 | 0.160 |
Why?
|
| Quality Assurance, Health Care | 1 | 2021 | 207 | 0.160 |
Why?
|
| Models, Cardiovascular | 4 | 2011 | 185 | 0.150 |
Why?
|
| Mitochondria, Heart | 2 | 1996 | 60 | 0.150 |
Why?
|
| Membrane Lipids | 1 | 1998 | 33 | 0.150 |
Why?
|
| Inflammation Mediators | 3 | 2016 | 246 | 0.150 |
Why?
|
| Retrospective Studies | 8 | 2024 | 16338 | 0.150 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2011 | 230 | 0.150 |
Why?
|
| Rats | 12 | 2015 | 3728 | 0.150 |
Why?
|
| Collagen | 6 | 2022 | 317 | 0.150 |
Why?
|
| Stroke Volume | 7 | 2020 | 496 | 0.150 |
Why?
|
| Signal Transduction | 7 | 2013 | 4597 | 0.150 |
Why?
|
| RNA, Messenger | 11 | 2010 | 2814 | 0.150 |
Why?
|
| Troponin T | 2 | 2023 | 284 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 3 | 2016 | 31 | 0.140 |
Why?
|
| Cholinergic Antagonists | 1 | 2018 | 51 | 0.140 |
Why?
|
| Risk Management | 1 | 2018 | 68 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2021 | 371 | 0.140 |
Why?
|
| Professional-Patient Relations | 1 | 2018 | 83 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2019 | 288 | 0.140 |
Why?
|
| Cachexia | 2 | 2010 | 48 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 560 | 0.140 |
Why?
|
| Systole | 6 | 2003 | 200 | 0.140 |
Why?
|
| Students, Pharmacy | 1 | 2018 | 64 | 0.140 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2017 | 29 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2018 | 163 | 0.140 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2009 | 128 | 0.140 |
Why?
|
| Vasoconstrictor Agents | 4 | 2011 | 135 | 0.140 |
Why?
|
| Phenotype | 8 | 2022 | 4270 | 0.140 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 429 | 0.130 |
Why?
|
| Middle Aged | 14 | 2024 | 26676 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 2 | 2009 | 22 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 2 | 2015 | 326 | 0.130 |
Why?
|
| Isoproterenol | 1 | 1996 | 104 | 0.130 |
Why?
|
| Electron Transport Complex IV | 1 | 1996 | 39 | 0.130 |
Why?
|
| Sex Factors | 7 | 2025 | 1275 | 0.130 |
Why?
|
| Muscle Contraction | 2 | 2000 | 188 | 0.130 |
Why?
|
| Myocardial Reperfusion | 3 | 2008 | 73 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 439 | 0.130 |
Why?
|
| Hyperthyroidism | 1 | 1996 | 26 | 0.130 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 94 | 0.130 |
Why?
|
| Mice, Mutant Strains | 3 | 2013 | 385 | 0.130 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 29 | 0.130 |
Why?
|
| Electronic Health Records | 2 | 2021 | 721 | 0.130 |
Why?
|
| MicroRNAs | 2 | 2013 | 858 | 0.130 |
Why?
|
| Myocarditis | 2 | 2015 | 130 | 0.120 |
Why?
|
| Alzheimer Disease | 2 | 2014 | 798 | 0.120 |
Why?
|
| Muscle, Skeletal | 3 | 2015 | 945 | 0.120 |
Why?
|
| Multienzyme Complexes | 2 | 2006 | 89 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2015 | 22 | 0.120 |
Why?
|
| Cell Lineage | 1 | 2017 | 350 | 0.120 |
Why?
|
| Anesthetics | 2 | 2008 | 79 | 0.120 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2015 | 36 | 0.120 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2015 | 4 | 0.120 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2015 | 5 | 0.120 |
Why?
|
| Cardiovirus Infections | 1 | 2015 | 7 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2015 | 61 | 0.120 |
Why?
|
| Energy Intake | 1 | 1997 | 493 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2015 | 217 | 0.120 |
Why?
|
| Dehydration | 1 | 2014 | 39 | 0.120 |
Why?
|
| Ultrasonography | 4 | 2011 | 939 | 0.110 |
Why?
|
| Prevalence | 3 | 2018 | 2458 | 0.110 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2014 | 13 | 0.110 |
Why?
|
| Diuretics | 2 | 2014 | 167 | 0.110 |
Why?
|
| Obesity | 2 | 2021 | 2244 | 0.110 |
Why?
|
| Stress, Physiological | 2 | 2015 | 256 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 657 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2006 | 45 | 0.110 |
Why?
|
| Receptors, CCR2 | 2 | 2011 | 26 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2182 | 0.110 |
Why?
|
| Cardiac Output | 1 | 1994 | 170 | 0.110 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2021 | 17 | 0.110 |
Why?
|
| Equipment Failure Analysis | 3 | 2009 | 85 | 0.110 |
Why?
|
| Biomarkers | 6 | 2023 | 3105 | 0.100 |
Why?
|
| Global Health | 1 | 2018 | 570 | 0.100 |
Why?
|
| Texas | 2 | 2024 | 3571 | 0.100 |
Why?
|
| Dogs | 5 | 1998 | 772 | 0.100 |
Why?
|
| Respiratory System | 1 | 2013 | 97 | 0.100 |
Why?
|
| Administration, Inhalation | 1 | 2013 | 180 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 434 | 0.100 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 1992 | 7 | 0.100 |
Why?
|
| Rats, Inbred F344 | 5 | 1996 | 108 | 0.100 |
Why?
|
| Reperfusion Injury | 2 | 2004 | 114 | 0.100 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 1993 | 33 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 1 | 2014 | 212 | 0.100 |
Why?
|
| Heart Ventricles | 6 | 2017 | 783 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 615 | 0.100 |
Why?
|
| Phosphorylation | 6 | 2013 | 1640 | 0.100 |
Why?
|
| Arterial Pressure | 1 | 2013 | 112 | 0.100 |
Why?
|
| Diet | 3 | 2025 | 1138 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2016 | 505 | 0.100 |
Why?
|
| Electronic Mail | 1 | 2012 | 38 | 0.100 |
Why?
|
| Computer-Assisted Instruction | 1 | 2012 | 51 | 0.100 |
Why?
|
| Depression | 1 | 2021 | 1233 | 0.100 |
Why?
|
| RNA-Binding Proteins | 2 | 2007 | 578 | 0.100 |
Why?
|
| Muscles | 2 | 2010 | 292 | 0.100 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 151 | 0.100 |
Why?
|
| Biomedical Engineering | 2 | 2009 | 27 | 0.100 |
Why?
|
| Reproducibility of Results | 5 | 2013 | 2878 | 0.100 |
Why?
|
| Theft | 1 | 2012 | 5 | 0.100 |
Why?
|
| Desmin | 2 | 2004 | 21 | 0.100 |
Why?
|
| Apoptosis | 5 | 2007 | 1819 | 0.100 |
Why?
|
| Cicatrix | 1 | 2013 | 124 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2013 | 157 | 0.100 |
Why?
|
| Fraud | 1 | 2012 | 16 | 0.100 |
Why?
|
| Investments | 1 | 2012 | 11 | 0.100 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 289 | 0.100 |
Why?
|
| Carotid Artery Diseases | 1 | 2013 | 139 | 0.100 |
Why?
|
| Elder Abuse | 1 | 2012 | 24 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2015 | 760 | 0.090 |
Why?
|
| Body Weight | 4 | 2010 | 989 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2016 | 483 | 0.090 |
Why?
|
| Cardiac Output, Low | 2 | 2003 | 67 | 0.090 |
Why?
|
| Transducers, Pressure | 1 | 2011 | 12 | 0.090 |
Why?
|
| Miniaturization | 1 | 2011 | 26 | 0.090 |
Why?
|
| Mitral Valve | 2 | 2008 | 252 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2013 | 1910 | 0.090 |
Why?
|
| Adenosine Triphosphate | 4 | 1993 | 280 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 131 | 0.090 |
Why?
|
| Motor Activity | 1 | 1994 | 521 | 0.090 |
Why?
|
| Colectomy | 1 | 2011 | 73 | 0.090 |
Why?
|
| Cysteine | 1 | 2011 | 139 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 141 | 0.090 |
Why?
|
| Actins | 2 | 2004 | 346 | 0.090 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2004 | 157 | 0.090 |
Why?
|
| Survival Rate | 6 | 2024 | 2051 | 0.090 |
Why?
|
| Aortic Valve Stenosis | 2 | 2005 | 338 | 0.090 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2012 | 164 | 0.090 |
Why?
|
| Adult | 9 | 2024 | 29460 | 0.080 |
Why?
|
| Basilar Artery | 1 | 2010 | 25 | 0.080 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 1994 | 320 | 0.080 |
Why?
|
| Anorexia | 1 | 2010 | 23 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 20 | 0.080 |
Why?
|
| Electrocardiography | 5 | 2009 | 976 | 0.080 |
Why?
|
| Young Adult | 3 | 2024 | 9056 | 0.080 |
Why?
|
| Aortic Valve | 2 | 2008 | 444 | 0.080 |
Why?
|
| Metabolic Diseases | 1 | 2011 | 130 | 0.080 |
Why?
|
| United States | 5 | 2024 | 10884 | 0.080 |
Why?
|
| Ventricular Function | 2 | 2008 | 91 | 0.080 |
Why?
|
| Resuscitation | 2 | 1991 | 252 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 5 | 2013 | 465 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3402 | 0.080 |
Why?
|
| Incidence | 3 | 2014 | 3131 | 0.080 |
Why?
|
| Heart Arrest | 1 | 1994 | 357 | 0.080 |
Why?
|
| Adipokines | 1 | 2010 | 60 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 262 | 0.080 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 150 | 0.080 |
Why?
|
| Energy Metabolism | 2 | 2010 | 765 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 825 | 0.080 |
Why?
|
| Enzyme Activation | 5 | 2013 | 626 | 0.080 |
Why?
|
| Vasodilation | 1 | 2010 | 171 | 0.080 |
Why?
|
| Middle Cerebral Artery | 1 | 2010 | 114 | 0.080 |
Why?
|
| Potassium | 1 | 2010 | 284 | 0.080 |
Why?
|
| Heart Function Tests | 1 | 2009 | 58 | 0.080 |
Why?
|
| Fatigue | 1 | 2010 | 188 | 0.080 |
Why?
|
| Gene Expression | 7 | 2013 | 1554 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2011 | 195 | 0.080 |
Why?
|
| Plasmalogens | 2 | 1998 | 4 | 0.080 |
Why?
|
| Hemorheology | 2 | 2005 | 25 | 0.080 |
Why?
|
| Anesthetics, Inhalation | 1 | 2009 | 45 | 0.080 |
Why?
|
| Ligation | 3 | 2003 | 133 | 0.070 |
Why?
|
| Exercise Test | 2 | 2007 | 254 | 0.070 |
Why?
|
| Intracellular Membranes | 2 | 1998 | 63 | 0.070 |
Why?
|
| Mortality | 2 | 1991 | 238 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 1994 | 2906 | 0.070 |
Why?
|
| Mice, Inbred Strains | 3 | 2003 | 309 | 0.070 |
Why?
|
| Hyperemia | 1 | 2008 | 27 | 0.070 |
Why?
|
| Coronary Stenosis | 1 | 2009 | 77 | 0.070 |
Why?
|
| Stem Cells | 2 | 2011 | 710 | 0.070 |
Why?
|
| Cytokines | 4 | 2013 | 1293 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2016 | 802 | 0.070 |
Why?
|
| Wound Healing | 2 | 2013 | 457 | 0.070 |
Why?
|
| Insulin | 1 | 2013 | 1203 | 0.070 |
Why?
|
| Cell Movement | 1 | 2011 | 854 | 0.070 |
Why?
|
| Smad3 Protein | 1 | 2007 | 58 | 0.070 |
Why?
|
| Aspergillosis | 1 | 1987 | 43 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 1704 | 0.070 |
Why?
|
| Heroin Dependence | 1 | 1987 | 56 | 0.070 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 2007 | 7 | 0.070 |
Why?
|
| Time Factors | 5 | 2021 | 6301 | 0.070 |
Why?
|
| Adolescent | 4 | 2024 | 19414 | 0.070 |
Why?
|
| Receptors, Chemokine | 1 | 2007 | 45 | 0.070 |
Why?
|
| Thoracic Vertebrae | 1 | 1987 | 66 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2012 | 3675 | 0.070 |
Why?
|
| Dwarfism | 1 | 2007 | 97 | 0.070 |
Why?
|
| Heart Conduction System | 2 | 2004 | 147 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2007 | 2603 | 0.070 |
Why?
|
| Microcirculation | 1 | 2007 | 96 | 0.070 |
Why?
|
| Calcium Signaling | 2 | 2021 | 244 | 0.070 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2007 | 125 | 0.070 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2004 | 118 | 0.070 |
Why?
|
| Alternative Splicing | 2 | 2007 | 356 | 0.070 |
Why?
|
| Lumbar Vertebrae | 1 | 1987 | 111 | 0.070 |
Why?
|
| Catecholamines | 1 | 2006 | 59 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2017 | 97 | 0.060 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 1708 | 0.060 |
Why?
|
| Detergents | 2 | 1998 | 24 | 0.060 |
Why?
|
| Myotonic Dystrophy | 1 | 2007 | 149 | 0.060 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2005 | 52 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2006 | 174 | 0.060 |
Why?
|
| DNA-Binding Proteins | 5 | 2012 | 2061 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 576 | 0.060 |
Why?
|
| Mass Screening | 2 | 2021 | 783 | 0.060 |
Why?
|
| In Vitro Techniques | 4 | 2004 | 971 | 0.060 |
Why?
|
| Neoplasms | 3 | 2010 | 2794 | 0.060 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2004 | 22 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 1987 | 205 | 0.060 |
Why?
|
| Cell Survival | 3 | 2019 | 820 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2004 | 30 | 0.060 |
Why?
|
| Exercise Therapy | 2 | 2015 | 156 | 0.060 |
Why?
|
| Telomere | 2 | 2003 | 220 | 0.060 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2004 | 11 | 0.060 |
Why?
|
| Peptide Hormones | 1 | 2005 | 68 | 0.060 |
Why?
|
| Atrioventricular Node | 1 | 2004 | 18 | 0.060 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2004 | 72 | 0.060 |
Why?
|
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2004 | 4 | 0.060 |
Why?
|
| Genes, bcl-2 | 1 | 2004 | 9 | 0.060 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2006 | 237 | 0.060 |
Why?
|
| Tachycardia, Ventricular | 1 | 2006 | 192 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 135 | 0.060 |
Why?
|
| Heart Block | 1 | 2004 | 40 | 0.060 |
Why?
|
| Body Temperature | 1 | 2004 | 117 | 0.050 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2004 | 61 | 0.050 |
Why?
|
| Fatty Acids | 2 | 1998 | 344 | 0.050 |
Why?
|
| Genetic Therapy | 2 | 2005 | 688 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2002 | 70 | 0.050 |
Why?
|
| Action Potentials | 2 | 2021 | 502 | 0.050 |
Why?
|
| Inpatients | 2 | 2021 | 497 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1273 | 0.050 |
Why?
|
| Elasticity | 1 | 2003 | 92 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2025 | 314 | 0.050 |
Why?
|
| Myofibroblasts | 2 | 2013 | 77 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5169 | 0.050 |
Why?
|
| Homeostasis | 3 | 2012 | 704 | 0.050 |
Why?
|
| Coronary Disease | 3 | 2020 | 671 | 0.050 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2022 | 35 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2005 | 420 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2002 | 14 | 0.050 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2002 | 28 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2002 | 69 | 0.050 |
Why?
|
| Mitochondrial Diseases | 1 | 2004 | 132 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 805 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 2 | 1993 | 202 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3310 | 0.050 |
Why?
|
| Membrane Proteins | 3 | 2007 | 1538 | 0.050 |
Why?
|
| Kv1.5 Potassium Channel | 1 | 2021 | 9 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2023 | 1187 | 0.050 |
Why?
|
| Sheep, Domestic | 1 | 2021 | 17 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2003 | 331 | 0.050 |
Why?
|
| Organ Size | 3 | 2010 | 442 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1685 | 0.050 |
Why?
|
| Acceleration | 1 | 2021 | 26 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 1425 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2023 | 313 | 0.040 |
Why?
|
| Homebound Persons | 1 | 2021 | 16 | 0.040 |
Why?
|
| Dobutamine | 1 | 2021 | 56 | 0.040 |
Why?
|
| Neutrophils | 3 | 2007 | 381 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 1294 | 0.040 |
Why?
|
| Telomerase | 1 | 2001 | 169 | 0.040 |
Why?
|
| Vasoconstriction | 2 | 2011 | 98 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 314 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 126 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 495 | 0.040 |
Why?
|
| Health Promotion | 1 | 2023 | 386 | 0.040 |
Why?
|
| Medical Informatics | 1 | 2021 | 109 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2023 | 781 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 377 | 0.040 |
Why?
|
| Tantalum | 1 | 1999 | 7 | 0.040 |
Why?
|
| Radioisotopes | 1 | 1999 | 38 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2011 | 1496 | 0.040 |
Why?
|
| Ligands | 1 | 2020 | 538 | 0.040 |
Why?
|
| Papillary Muscles | 2 | 1996 | 20 | 0.040 |
Why?
|
| Animal Feed | 1 | 2019 | 77 | 0.040 |
Why?
|
| rho-Associated Kinases | 2 | 2011 | 53 | 0.040 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2019 | 48 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 112 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 565 | 0.040 |
Why?
|
| Cross-Linking Reagents | 1 | 1998 | 55 | 0.040 |
Why?
|
| Cell Size | 2 | 2013 | 84 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2000 | 430 | 0.040 |
Why?
|
| Diet, Protein-Restricted | 1 | 2019 | 81 | 0.040 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2017 | 21 | 0.040 |
Why?
|
| Appetite | 2 | 2010 | 34 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2021 | 390 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 581 | 0.040 |
Why?
|
| Serum Response Factor | 2 | 2012 | 29 | 0.040 |
Why?
|
| Pulse | 1 | 1997 | 29 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2017 | 69 | 0.030 |
Why?
|
| Chemokines | 2 | 2008 | 134 | 0.030 |
Why?
|
| Rabbits | 1 | 1998 | 718 | 0.030 |
Why?
|
| Manometry | 1 | 1997 | 57 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2017 | 64 | 0.030 |
Why?
|
| Receptors, Estrogen | 2 | 2013 | 794 | 0.030 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2019 | 193 | 0.030 |
Why?
|
| Palliative Care | 1 | 2021 | 432 | 0.030 |
Why?
|
| Isometric Contraction | 1 | 1996 | 22 | 0.030 |
Why?
|
| Myosins | 2 | 1994 | 47 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1997 | 121 | 0.030 |
Why?
|
| Kinetics | 2 | 2002 | 1330 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 3 | 2004 | 1339 | 0.030 |
Why?
|
| Cell Communication | 1 | 2017 | 167 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2011 | 493 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 239 | 0.030 |
Why?
|
| Thyroxine | 1 | 1996 | 65 | 0.030 |
Why?
|
| Malnutrition | 1 | 2019 | 209 | 0.030 |
Why?
|
| Oxygen | 2 | 2003 | 556 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2017 | 486 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2003 | 1243 | 0.030 |
Why?
|
| Thyroid Hormone Receptors alpha | 1 | 2015 | 14 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2015 | 48 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 391 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 408 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2019 | 1019 | 0.030 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2015 | 37 | 0.030 |
Why?
|
| Enalapril | 1 | 2015 | 14 | 0.030 |
Why?
|
| Relaxin | 1 | 2015 | 15 | 0.030 |
Why?
|
| Mutation | 2 | 2006 | 5906 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 443 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2021 | 766 | 0.030 |
Why?
|
| Myosin Heavy Chains | 2 | 2004 | 76 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2015 | 171 | 0.030 |
Why?
|
| Longevity | 1 | 2015 | 135 | 0.030 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 74 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2014 | 122 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2013 | 13 | 0.030 |
Why?
|
| Cell Nucleus | 2 | 2007 | 680 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2013 | 29 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 461 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2015 | 12272 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1071 | 0.030 |
Why?
|
| Luciferases | 1 | 2013 | 132 | 0.030 |
Why?
|
| Sirtuin 1 | 1 | 2013 | 43 | 0.030 |
Why?
|
| Corn Oil | 1 | 1993 | 11 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 874 | 0.030 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2013 | 10 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 312 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2013 | 107 | 0.030 |
Why?
|
| Constriction | 2 | 2003 | 50 | 0.030 |
Why?
|
| Thapsigargin | 1 | 1992 | 22 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1992 | 36 | 0.030 |
Why?
|
| Biological Transport, Active | 1 | 1993 | 87 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 75 | 0.030 |
Why?
|
| Dimethyl Sulfoxide | 1 | 1992 | 18 | 0.030 |
Why?
|
| Viral Load | 1 | 2015 | 389 | 0.030 |
Why?
|
| Oxalates | 1 | 1993 | 32 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 236 | 0.030 |
Why?
|
| Competitive Behavior | 1 | 2012 | 10 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 97 | 0.030 |
Why?
|
| Terpenes | 1 | 1992 | 28 | 0.030 |
Why?
|
| Proteinuria | 1 | 1993 | 105 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2013 | 102 | 0.030 |
Why?
|
| Protein Binding | 2 | 2007 | 1756 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 433 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1992 | 387 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2013 | 112 | 0.020 |
Why?
|
| Fish Oils | 1 | 1993 | 85 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2012 | 37 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2013 | 229 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 129 | 0.020 |
Why?
|
| Genotype | 2 | 2010 | 2569 | 0.020 |
Why?
|
| Models, Educational | 1 | 2012 | 74 | 0.020 |
Why?
|
| Disease Progression | 2 | 2011 | 2084 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 1993 | 70 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1992 | 443 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 16 | 0.020 |
Why?
|
| Rivastigmine | 1 | 2011 | 17 | 0.020 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2011 | 5 | 0.020 |
Why?
|
| Thiocyanates | 1 | 1991 | 10 | 0.020 |
Why?
|
| Calcium Channel Agonists | 1 | 2011 | 11 | 0.020 |
Why?
|
| Phenylcarbamates | 1 | 2011 | 15 | 0.020 |
Why?
|
| Second Messenger Systems | 1 | 1991 | 11 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2014 | 490 | 0.020 |
Why?
|
| Fluoresceins | 1 | 1991 | 35 | 0.020 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 2011 | 35 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2011 | 54 | 0.020 |
Why?
|
| Isotopes | 1 | 2011 | 27 | 0.020 |
Why?
|
| F2-Isoprostanes | 1 | 2011 | 20 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1395 | 0.020 |
Why?
|
| Monocytes | 1 | 2013 | 345 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 508 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1400 | 0.020 |
Why?
|
| DNA Primers | 2 | 2003 | 657 | 0.020 |
Why?
|
| Program Development | 1 | 2012 | 182 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1991 | 247 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2011 | 184 | 0.020 |
Why?
|
| Transgenes | 2 | 2004 | 336 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 1992 | 420 | 0.020 |
Why?
|
| Down-Regulation | 2 | 2005 | 692 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2011 | 221 | 0.020 |
Why?
|
| GTP Phosphohydrolases | 1 | 1991 | 147 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2010 | 91 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 556 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2011 | 307 | 0.020 |
Why?
|
| alpha-Linolenic Acid | 1 | 2010 | 15 | 0.020 |
Why?
|
| Hospitals, Veterans | 2 | 1991 | 350 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2010 | 97 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2012 | 136 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 101 | 0.020 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 1 | 2010 | 22 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 210 | 0.020 |
Why?
|
| Resistin | 1 | 2010 | 30 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2010 | 83 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2010 | 42 | 0.020 |
Why?
|
| Potassium Channel Blockers | 1 | 2010 | 84 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 440 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2010 | 81 | 0.020 |
Why?
|
| Sarcolemma | 1 | 1989 | 23 | 0.020 |
Why?
|
| Adiponectin | 1 | 2010 | 113 | 0.020 |
Why?
|
| Mitochondria, Muscle | 1 | 1989 | 34 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2013 | 374 | 0.020 |
Why?
|
| Logistic Models | 1 | 1994 | 1800 | 0.020 |
Why?
|
| Kidney | 1 | 2016 | 1360 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1017 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 158 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 4821 | 0.020 |
Why?
|
| Leptin | 1 | 2010 | 213 | 0.020 |
Why?
|
| Resource Allocation | 1 | 1988 | 52 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 149 | 0.020 |
Why?
|
| Research | 1 | 2010 | 261 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1988 | 107 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 681 | 0.020 |
Why?
|
| Urinary Incontinence | 1 | 1988 | 70 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2008 | 59 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2007 | 24 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2007 | 22 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 1991 | 438 | 0.020 |
Why?
|
| Base Sequence | 2 | 2003 | 3109 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2007 | 50 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 51 | 0.020 |
Why?
|
| Myotonin-Protein Kinase | 1 | 2007 | 45 | 0.020 |
Why?
|
| CELF1 Protein | 1 | 2007 | 48 | 0.020 |
Why?
|
| Aspergillus | 1 | 1987 | 27 | 0.020 |
Why?
|
| Aspergillus fumigatus | 1 | 1987 | 43 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 1306 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2007 | 104 | 0.020 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Spinal Diseases | 1 | 1987 | 45 | 0.020 |
Why?
|
| Amphotericin B | 1 | 1987 | 90 | 0.020 |
Why?
|
| Species Specificity | 1 | 2008 | 551 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1592 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 174 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2010 | 484 | 0.020 |
Why?
|
| Caspases | 1 | 2007 | 163 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 1114 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2007 | 89 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1987 | 171 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 130 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2001 | 1006 | 0.020 |
Why?
|
| Weight Loss | 1 | 2010 | 481 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1526 | 0.020 |
Why?
|
| Pressure | 1 | 2006 | 129 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1893 | 0.020 |
Why?
|
| Caffeine | 1 | 2006 | 71 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 1906 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1988 | 304 | 0.020 |
Why?
|
| CELF Proteins | 1 | 2005 | 13 | 0.020 |
Why?
|
| Central Nervous System Stimulants | 1 | 2006 | 127 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1987 | 408 | 0.020 |
Why?
|
| Mifepristone | 1 | 2005 | 135 | 0.020 |
Why?
|
| Epinephrine | 1 | 2006 | 177 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2005 | 95 | 0.010 |
Why?
|
| Peptide YY | 1 | 2005 | 19 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1720 | 0.010 |
Why?
|
| Penetrance | 1 | 2005 | 102 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 256 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 1465 | 0.010 |
Why?
|
| Ghrelin | 1 | 2005 | 52 | 0.010 |
Why?
|
| Myocardial Stunning | 1 | 2004 | 22 | 0.010 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2004 | 6 | 0.010 |
Why?
|
| Nuclear Respiratory Factors | 1 | 2004 | 8 | 0.010 |
Why?
|
| NF-E2-Related Factor 1 | 1 | 2004 | 8 | 0.010 |
Why?
|
| Adenosine Monophosphate | 1 | 2004 | 42 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2005 | 113 | 0.010 |
Why?
|
| Cyclin T | 1 | 2004 | 34 | 0.010 |
Why?
|
| rho-Specific Guanine Nucleotide Dissociation Inhibitors | 1 | 2004 | 8 | 0.010 |
Why?
|
| rho Guanine Nucleotide Dissociation Inhibitor alpha | 1 | 2004 | 10 | 0.010 |
Why?
|
| Connexin 43 | 1 | 2004 | 29 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 319 | 0.010 |
Why?
|
| Mitochondrial Swelling | 1 | 2004 | 7 | 0.010 |
Why?
|
| RNA Polymerase II | 1 | 2004 | 100 | 0.010 |
Why?
|
| Cyclins | 1 | 2004 | 102 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 210 | 0.010 |
Why?
|
| Connexins | 1 | 2004 | 60 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2004 | 426 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2007 | 793 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2004 | 325 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 398 | 0.010 |
Why?
|
| Point Mutation | 1 | 2004 | 351 | 0.010 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2004 | 68 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 396 | 0.010 |
Why?
|
| Tail | 1 | 2003 | 15 | 0.010 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2003 | 36 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2005 | 528 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3600 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 567 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 664 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2005 | 605 | 0.010 |
Why?
|
| Tristetraprolin | 1 | 2002 | 6 | 0.010 |
Why?
|
| Calcinosis | 1 | 2004 | 181 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 268 | 0.010 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2002 | 19 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2005 | 245 | 0.010 |
Why?
|
| Captopril | 1 | 2002 | 27 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2003 | 181 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2002 | 149 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 58 | 0.010 |
Why?
|
| Heart Septum | 1 | 2002 | 54 | 0.010 |
Why?
|
| Binding Sites | 1 | 2004 | 1305 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 88 | 0.010 |
Why?
|
| Heterozygote | 1 | 2004 | 672 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 940 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 263 | 0.010 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2000 | 5 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 297 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 801 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2004 | 879 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 391 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 780 | 0.010 |
Why?
|
| Chimera | 1 | 1999 | 83 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2002 | 462 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 126 | 0.010 |
Why?
|
| Ischemia | 1 | 2003 | 353 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 576 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 1999 | 5 | 0.010 |
Why?
|
| Gamma Cameras | 1 | 1999 | 6 | 0.010 |
Why?
|
| Prognosis | 1 | 1988 | 4683 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2011 | 3047 | 0.010 |
Why?
|
| Anesthesia | 1 | 2002 | 205 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 2000 | 151 | 0.010 |
Why?
|
| Algorithms | 1 | 2005 | 1630 | 0.010 |
Why?
|
| Cats | 1 | 1997 | 118 | 0.010 |
Why?
|
| Acute Disease | 1 | 2000 | 1095 | 0.010 |
Why?
|
| Mammals | 1 | 1997 | 257 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 3175 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1997 | 776 | 0.010 |
Why?
|
| Oleic Acids | 1 | 1993 | 10 | 0.010 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 1993 | 25 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 1284 | 0.010 |
Why?
|
| Physical Endurance | 1 | 1993 | 45 | 0.010 |
Why?
|
| Carnitine | 1 | 1993 | 74 | 0.010 |
Why?
|
| Perfusion | 1 | 1993 | 206 | 0.010 |
Why?
|
| Affinity Labels | 1 | 1991 | 15 | 0.010 |
Why?
|
| Photochemistry | 1 | 1991 | 22 | 0.010 |
Why?
|
| Precipitating Factors | 1 | 1991 | 1 | 0.010 |
Why?
|
| Digitalis Glycosides | 1 | 1991 | 5 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1991 | 42 | 0.010 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1991 | 30 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1991 | 161 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 309 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1991 | 295 | 0.010 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1991 | 74 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1991 | 262 | 0.010 |
Why?
|
| Disclosure | 1 | 1991 | 150 | 0.010 |
Why?
|
| Attitude to Health | 1 | 1991 | 255 | 0.000 |
Why?
|
| Biological Transport | 1 | 1990 | 355 | 0.000 |
Why?
|
| Glucose | 1 | 1993 | 876 | 0.000 |
Why?
|
| Urinary Incontinence, Stress | 1 | 1988 | 31 | 0.000 |
Why?
|
| Physician-Patient Relations | 1 | 1991 | 427 | 0.000 |
Why?
|
| Communication | 1 | 1991 | 507 | 0.000 |
Why?
|
| Activities of Daily Living | 1 | 1988 | 394 | 0.000 |
Why?
|
| Population Surveillance | 1 | 1988 | 390 | 0.000 |
Why?
|